SL LINK Co., Ltd., as a partner of international semiconductor giants, has long been dedicated to precision technology research. The company has long been accustomed to precision technology thinking and ventured into the field of regenerative medicine research and development years ago. In order to introduce semiconductor nanofabrication technology standards into regenerative medicine, SL LINK joined hands with Hexun Bioscience Co., Ltd., to establish the GTP Laboratory and founded the Cell Innovation Research and Development Center, inviting companies such as CytoArm and 3D Global Biotech Inc. to participate in research. 

In 2023, CytoArm 's research results achieved significant success, authorizing SL LINK to conduct clinical trials of a new drug. This new drug, named Armed-T-CD19, targets the current CAR-T-CD19 target, addressing blood cancers such as leukemia and multiple myeloma. Due to its high safety, simplicity of operation, and cost only 1/10 of CAR-T, Armed-T-CD19 is expected to change the landscape of CAR-T therapy globally, bringing more hope and possibilities to patients. 

Resource (Mandarin): 追日潤集團取得賽昂授權發展Arm-T -CD19 血癌細胞藥